Evidence map›Paper›PMID 37004023›Full record

Observational studyCardiovascular diabetology2023

Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2.

Alexander Kogan, Avishay Grupper, Avi Sabbag, Eilon Ram, Tamer Jamal, Eyal Nof, Enrique Z Fisman, Shany Levin, Roy Beinart, Jonathan Frogel and 2 more

Erratum issuedOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alexander KoganDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel. alexanderkogan140@hotmail.com.
Avishay GrupperDivision of Cardiology, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Avi SabbagDivision of Cardiology, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Eilon RamDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Tamer JamalDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Eyal NofDivision of Cardiology, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Enrique Z FismanSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shany LevinDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Roy BeinartDivision of Cardiology, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Jonathan FrogelDepartment of Anesthesiology, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Ehud RaananiDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Leonid SternikDepartment of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation.

methodsWe performed an observational cohort study in Israel's largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate.

resultsThe study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time-130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009).

conclusionSurgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group.

Indexed as

Atrial FibrillationCardiac Surgical ProceduresDiabetes Mellitus, Type 2HumansRisk FactorsTreatment OutcomeAtrial fibrillationDiabetes mellitus type 2Long-term follow-upSurgical ablation

Identifiers

PMID37004023
PMCPMC10067240
OpenAlexW4362467750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.